Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josefien W. Hommes has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Bas G. J. Surewaard

    Snyder Institute for Chronic Diseases, University of Calgary

    6 shared publications
  • David E. Heinrichs

    Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada

    2 shared publications
  • Lindsey M. Orthner

    Department of Microbiology, Immunology, and Infectious Disease. Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada

    2 shared publications
  • Ronald S. Flannagan

    Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada

    2 shared publications
  • Adrien Guillot

    Department of Hepatology & Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany

    1 shared publication
  • Alexander R. Horswill

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA

    1 shared publication

Latest Publications

  • Open Access

    A niche-specific role for ArlRS enables Staphylococcus aureus growth within Kupffer cells

    by Josefien W. Hommes, Lindsey M. Orthner, Fardau van der Wal, Ronald S. Flannagan, Raymond Shim, Luisa Samaniego Barrón, Mai Dao, Iñigo Lasa, Alexander R. Horswill, David E. Heinrichs, et al.

    Staphylococcus aureus bloodstream infections cause severe morbidity and mortality despite antibiotic therapy. We previously identified Kupffer cells (KCs) as the primary hepatic macrophages that rapidly clear circulating S. aureus , yet a subset of bacteria survives intracellularly and seeds systemic infection. Here, using spinning-disk intravital and super-resolution microscopy, we show that bacterial two-component system (TCS) signaling is required for intracellular replication within KCs in vivo . A global mutant lacking all non-essential TCSs failed to form intracellular microcolonies, and targeted analysis identified the ArlRS system as specifically required for KC replication. Δ arlRS bacteria remained as single non-replicating organisms within KCs, exhibited reduced dissemination and kidney abscess formation, and showed attenuated virulence with improved host survival. Complementation with arlRS restored the wildtype phenotype. Notably, the intracellular replication defect was not observed in primary or cultured macrophages, indicating that ArlRS-dependent replication is highly niche-specific and not reproduced by conventional in vitro models. Furthermore, restricting the KC reservoir with vancomycin treatment after infection further reduced renal infection by Δ arlRS bacteria. These findings identify ArlRS as a critical regulator of intracellular replication within KCs and establish the KC intracellular reservoir as a key driver of S. aureus pathogenesis and a potential therapeutic target during bloodstream infection.

  • Open Access

    Adeno-associated virus delivery of anti-alpha toxin monoclonal antibodies confers protection against Staphylococcus aureus infections

    by Josefien W. Hommes, Madison E. Hughes, Derek Cheung, Björn Petri, Lindsey M. Orthner, Tristan J. van der Linden, Bart W. Bardoel, Simran K. Deo, Deepak T. Patel, Ronald S. Flannagan, et al.

    Staphylococcus aureus is a major cause of infections, ranging from mild skin conditions to severe life-threatening systemic diseases. Despite decades of effort, vaccine development has been unsuccessful, highlighting the need for alternative approaches. One promising candidate is MEDI4893 (Suvratoxumab), a monoclonal antibody that neutralizes α-toxin (AT), a key virulence factor with diverse functions including cellular lysis and induction of platelet aggregation during sepsis. MEDI4893 has demonstrated efficacy in various preclinical models of infection and showed encouraging results in a phase IIb clinical trial for ventilator-associated pneumonia. However, as an exogenous antibody, MEDI4893 is limited by its short half-life, high production costs, and restricted availability. To overcome these challenges, we investigated vectored immunoprophylaxis as a novel strategy for long-term protection. This approach uses an adeno-associated viral vector (AAV) to deliver the MEDI4893 gene, enabling sustained in vivo antibody expression. Following AAV-MEDI4893 administration, mice developed high and stable antibody levels in plasma and detectable titers at mucosal surfaces. Using intravital microscopy, we observed that vector-mediated MEDI4893 effectively prevented AT-induced platelet aggregation and microvascular thrombosis, thereby protecting animals from the lethal effects of intravenous toxin challenge. Infection studies confirmed that this protective effect extended to clinically relevant models. In murine pneumonia models, treated mice showed improved survival and reduced sickness behavior despite similar bacterial burdens, while in skin infection models, they were protected from dermal necrosis and exhibited lower bacterial loads. These findings highlight that AT is a major driver of pathology across multiple tissues and that its neutralization can mitigate disease severity. Together, our results demonstrate that AAV-mediated delivery of MEDI4893 provides durable, protective antibody levels and effectively neutralizes AT in vivo . This strategy represents a cost-effective, long-lasting alternative to traditional monoclonal antibody therapy and offers a promising prophylactic approach to mitigate S. aureus infections in the absence of a vaccine.


  • Kupffer cell reverse migration into the liver sinusoids mitigates neonatal sepsis and meningitis

    by Bruna Araujo David, Jawairia Atif, Fernanda Vargas e Silva Castanheira, Tamanna Yasmin, Adrien Guillot, Yeni Ait Ahmed, Moritz Peiseler, Josefien W. Hommes, Lilian Salm, Marie-Anne Brundler, et al.

    In adults, liver-resident macrophages, or Kupffer cells (KCs), reside in the sinusoids and sterilize circulating blood by capturing rapidly flowing microbes. We developed quantitative intravital imaging of 1-day-old mice combined with transcriptomics, genetic manipulation, and in vivo infection assays to interrogate increased susceptibility of newborns to bloodstream infections. Whereas 1-day-old KCs were better at catching Escherichia coli in vitro, we uncovered a critical 1-week window postpartum when KCs have limited access to blood and must translocate from liver parenchyma into the sinusoids. KC migration was independent of the microbiome but depended on macrophage migration inhibitory factor, its receptor CD74, and the adhesion molecule CD44. On the basis of our findings, we propose a model of progenitor macrophage seeding of the liver sinusoids via a reverse transmigration process from liver parenchyma. These results also illustrate the importance of developing newborn mouse models to understand newborn immunity and disease.


  • Open Access

    Novel Pentafluorosulfanyl-containing Triclocarban Analogs selectively kill Gram-positive bacteria

    by Ali Pormohammad, Melika Moradi, Josefien W. Hommes, Eugènia Pujol, Lieve Naesens, Santiago Vázquez, Bas G. J. Surewaard, Mohammad Zarei, Manuel Vazquez-Carrera, Raymond J. Turner

    The antibacterial and antibiofilm efficacy of our novel pentafluorosulfanyl-containing triclocarban analogs was explored against seven different Gram-positive and Gram-negative indicator strains. After initial screening, they had bactericidal and bacteriostatic activity against Gram-positive bacteria, especially Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus) in a very low concentration. Our results were compared with the most common antibiotic being used (Ciprofloxacin and Gentamycin); the novel components had significantly better antibacterial and antibiofilm activity in lower concentrations in comparison to the antibiotics. For instance, EBP- 59 minimum inhibitory concentration was < 0.0003 mM, while ciprofloxacin 0.08 mM. Further antibacterial activity of novel components was surveyed against 10 clinical antibiotic resistance MRSA isolates. Again, novel components had significantly better antibacterial and antibiofilm activity in comparison with antibiotics. Mechanistic studies have revealed that none of these novel compounds exhibit any effect on the reduced thiol, disrupting iron sulfur clusters, or hydrogen peroxide pathways. Instead, their impact is attributed to the disruption of the Gram-positive bacterial cell membrane. Toxicity and safety testing on tissue cell culture showed promising results for the safety of components to the host.

  • Open Access

    Intracellular Habitation of Staphylococcus aureus: Molecular Mechanisms and Prospects for Antimicrobial Therapy

    by Josefien W. Hommes, Bas G. J. Surewaard

    Methicillin-resistant Staphylococcus aureus (MRSA) infections pose a global health threat, especially with the continuous development of antibiotic resistance. As an opportunistic pathogen, MRSA infections have a high mortality rate worldwide. Although classically described as an extracellular pathogen, many studies have shown over the past decades that MRSA also has an intracellular aspect to its infectious cycle, which has been observed in vitro in both non-professional as well as professional phagocytes. In vivo, MRSA has been shown to establish an intracellular niche in liver Kupffer cells upon bloodstream infection. The staphylococci have evolved various evasion strategies to survive the antimicrobial environment of phagolysosomes and use these compartments to hide from immune cells and antibiotics. Ultimately, the host cells get overwhelmed by replicating bacteria, leading to cell lysis and bacterial dissemination. In this review, we describe the different intracellular aspects of MRSA infection and briefly mention S. aureus evasion strategies. We discuss how this intracellular niche of bacteria may assist in antibiotic tolerance development, and lastly, we describe various new antibacterial strategies that target the intracellular bacterial niche.


  • Open Access

    High density lipoproteins mediate in vivo protection against staphylococcal phenol-soluble modulins

    by Josefien W. Hommes, Rachel M. Kratofil, Sigrid Wahlen, Carla J. C. de Haas, Reeni B. Hildebrand, G. Kees Hovingh, Micheal Otto, Miranda van Eck, Menno Hoekstra, Suzanne J. A. Korporaal, et al.

    Staphylococcus aureus virulence has been associated with the production of phenol-soluble modulins (PSMs). These PSMs have distinct virulence functions and are known to activate, attract and lyse neutrophils. These PSM-associated biological functions are inhibited by lipoproteins in vitro. We set out to address whether lipoproteins neutralize staphylococcal PSM-associated virulence in experimental animal models. Serum from both LCAT an ABCA1 knockout mice strains which are characterised by near absence of high-density lipoprotein (HDL) levels, was shown to fail to protect against PSM-induced neutrophil activation and lysis in vitro. Importantly, PSM-induced peritonitis in LCAT−/− mice resulted in increased lysis of resident peritoneal macrophages and enhanced neutrophil recruitment into the peritoneal cavity. Notably, LCAT−/− mice were more likely to succumb to staphylococcal bloodstream infections in a PSM-dependent manner. Plasma from homozygous carriers of ABCA1 variants characterized by very low HDL-cholesterol levels, was found to be less protective against PSM-mediated biological functions compared to healthy humans. Therefore, we conclude that lipoproteins present in blood can protect against staphylococcal PSMs, the key virulence factor of community-associated methicillin resistant S. aureus.


  • Open Access

    Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review

    by Josefien W. Hommes, Rik J. Verheijden, Karijn P. M. Suijkerbuijk, Dörte Hamann

    Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of patients with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), negative feedback mechanisms of the immune system are inhibited, potentially resulting in very durable anti-tumor responses. Despite their promise, ICIs can also elicit auto-immune toxicities. These immune-related adverse events (irAEs) can be severe and sometimes even fatal. Therefore, being able to predict severe irAEs in patients would be of added value in clinical decision making. A search was performed using “adverse events”, “immune checkpoint inhibitor”, “biomarker”, and synonyms in PubMed, yielding 3580 search results. After screening title and abstract on the relevance to the review question, statistical significance of reported potential biomarkers, and evaluation of the remaining full papers, 35 articles were included. Five additional reports were obtained by means of citations and by using the similar article function on PubMed. The current knowledge is presented in comprehensive tables summarizing blood-based, immunogenetic and microbial biomarkers predicting irAEs prior to and during ICI therapy. Until now, no single biomarker has proven to be sufficiently predictive for irAE development. Recommendations for further research on this topic are presented.